The overall goal of the University of Kansas Alzheimer's Disease Core Center (KU ADCC) Neuromaging Core is to enhance the neuroimaging infrastructure and facilitate increased research in aging and Alzheimer's disease for researchers at the University of Kansas and nearby institutions. The Neuroimaging Core builds on the established resources of the (i) KU Hoglund Brain Imaging Center that brings together, in a specialized research building, a unique array of human (3 Tesla) and animal (9.4 Tesla) MRI and cortical (151 channel) and fetal (83 channel) magnetoencephalography (MEG), and the (ii) KU Hospital that provides positron emission tomography as well as a strong faculty of imaging scientists with outstanding experience across the modalities. Accordingly, the Neuroimaging Core is ideally resourced to support current and future investigators who use imaging as a research tool. This goal will be achieved through three specific aims that provide (i) state-of-the-art imaging facilities and professional neuroimaging support, (ii) advanced education in imaging sciences and (iii) novel imaging approaches to AD investigators of the University of Kansas, the state of Kansas, and the Kansas City metropolitan area.
The Specific Aims of the KU ADCC Neuroimaging Core are Aim 1. Provide an integrated imaging environment with advanced scientific support and subsidized scans for AD research Aim 2. Provide advanced training, and education in imaging for ADCC investigators.
Aim 3. Develop novel imaging techniques for studies in AD.
Neuroimaging provides a non-invasive means to measure structure and function of the living human brain. The Neuroimaging Core will support scientists investigating Alzheimer's and other neurodegenerative diseases of aging by providing access to state-of-the-art imaging, education and training in imaging modalities, and novel imaging methods.
|Menta, Blaise W; Swerdlow, Russell H (2018) An Integrative Overview of Non-Amyloid and Non-Tau Pathologies in Alzheimer's Disease. Neurochem Res :|
|Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211|
|Ptomey, Lauren T; Szabo, Amanda N; Willis, Erik A et al. (2018) Remote Exercise for Adults with Down Syndrome. Transl J Am Coll Sports Med 3:60-65|
|Deng, Yue; Jiang, Beichen; Rankin, Carolyn L et al. (2018) Methionine sulfoxide reductase A (MsrA) mediates the ubiquitination of 14-3-3 protein isotypes in brain. Free Radic Biol Med 129:600-607|
|Perales, Jaime; Hinton, Ladson; Burns, Jeffrey et al. (2018) Cardiovascular health and cognitive function among Mexican older adults: cross-sectional results from the WHO Study on Global Ageing and Adult Health. Int Psychogeriatr 30:1827-1836|
|Qian, Winnie; Fischer, Corinne E; Schweizer, Tom A et al. (2018) Association Between Psychosis Phenotype and APOE Genotype on the Clinical Profiles of Alzheimer's Disease. Curr Alzheimer Res 15:187-194|
|Perales, Jaime; Moore, W Todd; Fernandez, Cielo et al. (2018) Feasibility of an Alzheimer's disease knowledge intervention in the Latino community. Ethn Health :1-12|
|Gallagher, Damien; Kiss, Alex; Lanctot, Krista et al. (2018) Depression and Risk of Alzheimer Dementia: A Longitudinal Analysis to Determine Predictors of Increased Risk among Older Adults with Depression. Am J Geriatr Psychiatry 26:819-827|
|Gupta, Aditi; Thomas, Tashra S; Klein, Jeffrey A et al. (2018) Discrepancies between Perceived and Measured Cognition in Kidney Transplant Recipients: Implications for Clinical Management. Nephron 138:22-28|
|Haaksma, Miriam L; Calderón-Larrañaga, Amaia; Olde Rikkert, Marcel G M et al. (2018) Cognitive and functional progression in Alzheimer disease: A prediction model of latent classes. Int J Geriatr Psychiatry 33:1057-1064|
Showing the most recent 10 out of 333 publications